Qrono Announces Development Collaboration for Long-Acting Psychiatric Medicines

Share Article

Qrono and Phebra will develop long-acting injectable products based on the QronoMetrics™ platform with a primary focus on psychiatry

Qrono Inc.

Qrono Inc.

Our partnership with Phebra is a significant step forward for Qrono

Qrono Inc., a specialty pharmaceutical company focused on long-acting injectables (LAIs), today announced a development collaboration with the Australian critical medicine company, Phebra Pty Ltd., to develop LAI medications to treat serious mental disorders such as schizophrenia.

LAI medicines can offer improved therapeutic benefits over oral formulations, including better bioavailability, improved adherence, and reduced differences in peak and trough drug plasma levels. These therapeutic benefits are especially pronounced for second-generation antipsychotics and other psychiatric drugs, leading to improved therapeutic outcomes and a reduction of the risk of relapse.

“Our partnership with Phebra is a significant step forward for Qrono," commented Larry Zana, CEO of Qrono. “We are excited to collaborate with Phebra to demonstrate the utility of the QronoMetrics™ platform in rapidly developing LAI formulations and underscoring the unique potential of computational drug delivery.”

“We see tremendous potential in applying Qrono’s technology to develop new medicines and extend our range of specialized injectables,” said Phebra CEO Dr. Mal Eutick. “By combining Qrono’s proven capabilities in long-acting formulation development with Phebra’s strong track record of successfully commercializing sterile injectable products, we are creating an opportunity to bring a new therapeutic option to psychiatric patients.”

Qrono’s proprietary computational drug delivery platform, called QronoMetrics™, has demonstrated the ability to create LAIs faster and with less clinical and technical risk than legacy practice.

About Qrono: Qrono reformulates FDA approved drug products and creates new, long-acting injectable (LAI) medications with improved clinical and economic benefits. Qrono’s product pipeline focuses on therapeutic areas where LAIs offer high therapeutic and economic value, such as addressing high non-adherence or solving specific drug delivery challenges. The company uses its computational drug delivery technology to design LAIs significantly faster than legacy practice and with reduced clinical and technical risk. Qrono media contact: Larry Zana, CEO Phone: +1-412-213-8788. Email: lzana(at)qrono(dot)com

About Phebra: Phebra Pty Ltd. is an Australian based specialty pharmaceutical company that develops and markets critical medicines in Australia, New Zealand, Asia, Canada and parts of Europe. Phebra specializes in the development, manufacture, marketing and distribution of innovative medicines for the hospital market, with focus in nine therapeutic areas including antidotes, oncology and pain. The company is dedicated to providing high quality medicines for serious and life-threatening conditions and to meeting the needs of the hospital specialty pharmaceutical market. Phebra media contact: The Premier Communications Group +61 411 254 390

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Larry Zana
Qrono, Inc.
+1.412.213.8788
Email >
Follow us on
Visit website